Janus kinase inhibitors in autoimmune diseases

Annals of the Rheumatic Diseases

Volumn 72, Issue SUPPL. 2, 2013, Pages

  O'Shea, John J ^a   Kontzias, Apostolos ^a   Yamaoka, Kunihiro ^b   Tanaka, Yoshiya ^b   Laurence, Arian ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; AC 340; AC 480; ADALIMUMAB; BARICITINIB; BMS 911543; CEP 33779; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLPG 0634; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; LESTAURTINIB; METHOTREXATE; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN KINASE TYK2; R 348; R 723; RUXOLITINIB; STEROID; TOCILIZUMAB; TOFACITINIB; UNCLASSIFIED DRUG; VX 509;

ALLERGY; ANEMIA; ANKYLOSING SPONDYLITIS; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; CHRONIC DRUG ADMINISTRATION; DISORDERS OF LIPID METABOLISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRY EYE; ENTERITIS; ENZYME INHIBITION; GENETIC SUSCEPTIBILITY; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOPATHOLOGY; INTRACELLULAR SIGNALING; KIDNEY GRAFT REJECTION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VASCULITIS;

ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; JANUS KINASES; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84876222093     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202576     Document Type: Article

References (50)

1. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537-45.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
3. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
4. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713-25.
5. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;377:2127-37.
6. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998;16:293-322. (Pubitemid 28183367)
7. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21. (Pubitemid 24217131)
8. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012;36:503-14.
9. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity 2012;36:515-28.
10. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004;21:461-5. (Pubitemid 39370502)
11. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010;10:89-102.
12. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009;9:556-67.
13. Hunter T. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol Cell 2007;28:730-8. (Pubitemid 350217067)
14. Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-83. (Pubitemid 47327415)
15. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
16. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98.
17. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363:1117-27.
18. Williams W, Scherle P, Shi J, et al. A randomized placebocontrolled study of INCB018424, a selective Janus kinase1& 2 (JAK1&2) inhibitor in rheumatoid arthritis. Arthritis Rheum (Abstract). 2008;58:S431.
19. Kwatra SG, Dabade TS, Gustafson CJ, et al. JAK inhibitors in psoriasis: a promising new treatment modality. J Drugs Dermatol 2012;11:913-18.
20. Keystone E, Taylor P, Genovese M, et al. 12-Week results of a Phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAJ/JAK2 inhibitor, in combination with traditional DMARDs in patients with rheumatoid arthritis. Ann Rheum. Dis. (Abstract: LB0005). 2012;71(S3):152.
21. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234-43.
22. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
23. Liew SH, Nichols KK, Klamerus KJ, et al. Tofacitinib (CP-690,550), a Janus Kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology 2012;119:1328-35.
24. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
25. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
26. Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol 2009;129:2299-302.
27. Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011;63:1150-8.
28. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med (Research Support, Non-U.S. Gov't). 2012;367:616-24.
29. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905.
30. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012;64:617-29.
31. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis on methotrexate: 12-Month data from a 24-month Phase 3 randomized radiographicstudy. Arthritis Rheum Published Online First: 24 Jan 2013. doi: 10.1002/art.37816
32. Fleischmann R, Spencer-Green GT, Fan F, et al. Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA). Arthritis Rheum (Late breaking Abstract) 2011;63:LB3.
33. Vanhoutte FP, Mazur M, Namour F, et al. Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIa trial. Ann Rheum Dis (Abstract: 5175) 2012;71(S3):145.
34. Stump KL, Lu LD, Dobrzanski P, et al. A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Res Ther 2011;13:R68.
35. Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 2012;64:1790-8.
36. Rosengren S, Corr M, Firestein GS, et al. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012;71:440-7.
37. Yamaoka K, Kubo S, Sonomoto K, et al. A JAK inhibitor, tofacitinib reduces IL-6 and matrix metalloproteinase-3 production in rheumatoid arthritis with suppressed cartilage destruction. Arthritis Res Ther 2012;14(Suppl 1):P77.
38. LaBranche TP, Jesson MI, Radi ZA, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 2012;64:3531-42.
39. Chen M, Cheng A, Chen YQ, et al. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc Natl Acad Sci U S A 1997;94:6910-15.
40. Candotti F, Oakes SA, Johnston JA, et al. Structural and functional basis for JAK3-deficient severe combined immunodeficiency. Blood 1997;90:3996-4003. (Pubitemid 27484053)
41. Yoshida K, van den Berg TK, Dijkstra CD. The functional state of follicular dendritic cells in severe combined immunodeficient (SCID) mice: role of the lymphocytes. Eur J Immunol 1994;24:464-8. (Pubitemid 24041141)
42. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93:373-83. (Pubitemid 28232082)
43. McInnes IB, Kim H-Y, Lee S, et al. Phase 2 study of teh effects of open-label tofactinib (CP-690,550) and double blind atorvastatin on lipids in patients with active rheumatoid arthritis. Ann Rheum Dis (Abstract) 2011;70(Suppl 3):169.
44. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
45. Kawasaki M, Fujishiro M, Yamaguchi A, et al. Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus. Lupus 2011;20:1231-9.
46. Wang S, Yang N, Zhang L, et al. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice. Lupus 2010;19:1171-80.
47. Obermoser G, Pascual V. The interferon-alpha signature of systemic lupus erythematosus. Lupus 2010;19:1012-19.
48. Crow MK. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 2010;12(Suppl 1):S5.
49. Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther 2011;13:228.
50. Kudlacz E, Conklyn M, Andresen C, et al. The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 2008;582:154-61.